Danielle Antalffy
Stock Analyst at UBS
(3.69)
# 791
Out of 5,131 analysts
195
Total ratings
49.56%
Success rate
8%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGHT Sight Sciences | Maintains: Buy | $7 → $12 | $7.41 | +61.94% | 3 | Dec 23, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $96.89 | -6.08% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $110.91 | +30.74% | 3 | Dec 23, 2025 | |
| PRCT PROCEPT BioRobotics | Initiates: Buy | $62 | $31.33 | +97.89% | 4 | Dec 12, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $92 | $83.01 | +10.83% | 13 | Dec 5, 2025 | |
| MDT Medtronic | Maintains: Neutral | $95 → $102 | $96.95 | +5.21% | 12 | Nov 19, 2025 | |
| PODD Insulet | Upgrades: Buy | $355 → $400 | $278.55 | +43.60% | 13 | Nov 19, 2025 | |
| TMCI Treace Medical Concepts | Maintains: Neutral | $6.5 → $5.85 | $2.79 | +109.68% | 8 | Nov 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $96 → $88 | $91.45 | -3.77% | 6 | Nov 6, 2025 | |
| INMD InMode | Maintains: Neutral | $16 → $16 | $14.49 | +10.42% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $70.98 | +33.84% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $20.15 | +4.22% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $572.75 | +4.76% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $140 | $95.72 | +46.26% | 14 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $209.72 | +2.04% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $8 | $10.09 | -20.71% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $26.95 | +111.50% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $17 | $21.35 | -20.37% | 15 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $58 | $37.60 | +54.26% | 13 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $124.64 | +18.74% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $366 → $370 | $361.37 | +2.39% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $4.27 | -47.31% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $5.57 | +14,711.49% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $31.55 | -55.63% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $67.48 | +48.19% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $16.94 | -29.16% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $36.52 | +23.22% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $202.74 | +35.64% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $4.23 | +372.81% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.21 | +576.33% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $7.11 | +743.88% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.70 | +2,039.50% | 1 | Sep 1, 2020 |
Sight Sciences
Dec 23, 2025
Maintains: Buy
Price Target: $7 → $12
Current: $7.41
Upside: +61.94%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $96.89
Upside: -6.08%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $110.91
Upside: +30.74%
PROCEPT BioRobotics
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $31.33
Upside: +97.89%
Edwards Lifesciences
Dec 5, 2025
Maintains: Neutral
Price Target: $90 → $92
Current: $83.01
Upside: +10.83%
Medtronic
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $96.95
Upside: +5.21%
Insulet
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $278.55
Upside: +43.60%
Treace Medical Concepts
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $2.79
Upside: +109.68%
Zimmer Biomet Holdings
Nov 6, 2025
Maintains: Sell
Price Target: $96 → $88
Current: $91.45
Upside: -3.77%
InMode
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $14.49
Upside: +10.42%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $70.98
Upside: +33.84%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $20.15
Upside: +4.22%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $572.75
Upside: +4.76%
Oct 23, 2025
Maintains: Buy
Price Target: $135 → $140
Current: $95.72
Upside: +46.26%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $209.72
Upside: +2.04%
Aug 8, 2025
Maintains: Neutral
Price Target: $16 → $8
Current: $10.09
Upside: -20.71%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $26.95
Upside: +111.50%
Aug 7, 2025
Maintains: Neutral
Price Target: $20 → $17
Current: $21.35
Upside: -20.37%
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $37.60
Upside: +54.26%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $124.64
Upside: +18.74%
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $361.37
Upside: +2.39%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $4.27
Upside: -47.31%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $5.57
Upside: +14,711.49%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $31.55
Upside: -55.63%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $67.48
Upside: +48.19%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $16.94
Upside: -29.16%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $36.52
Upside: +23.22%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $202.74
Upside: +35.64%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $4.23
Upside: +372.81%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.21
Upside: +576.33%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $7.11
Upside: +743.88%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.70
Upside: +2,039.50%